An interventional study of Fish skin and Cadaver skin in Burns, sponsored by Kerecis Ltd.. Completed at 1 site in United States. Open to participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-06.
Sponsored by Kerecis Ltd. (part of Coloplast A/S) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 336 studies in Burns with a site in United States — 40 open to participants now, 52 under way, 5 of them phase 3. Burns · United States.
Among the 336 studies in Burns with a site in United States, this one is the 225th largest by enrollment of the 272 interventional ones that give a count, is one of 20 that started in 2019, is one of 152 with no phase, and was the 226th registered.
906 studies on the registry are indexed under Burns; 165 are open to participants now.
Browse Burns studies →40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:
Jason Sperry · Sites in United States
Ages 18–75
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18+
University of Tennessee · Sites in United States
Ages 18–80
The Metis Foundation · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 85 Burns studies recruiting now, 38 (45%) set no upper age limit and 38 (45%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.
This study: 22 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
336 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 56 · Phase 3 30 · Phase 4 25
First in 1992; this study’s year is marked. 20 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 40 across 664 interventional studies indexed under Burns.
Median enrollment 26 across the 272 interventional studies, 59 across the 61 observational. Of the 225 that completed or were terminated, 74 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 336 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kerecis Ltd., one of the names counted as Coloplast A/S. Under that name alone:
Kerecis Ltd. is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
Coloplast A/S has 3 studies filed under Burns — fewer than ten, so there is no comparison to draw.
10 of the studies in Burns with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05223998The Metis FoundationManual Implantation of Full-Thickness Skin Microcolumns | 2026-12 |
| NCT07317271Johns Hopkins UniversityVR-PMR for Post-Burn Symptoms | 2026-12 |
| NCT05462860The Metis FoundationSuprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds | 2026-12-09 |
| NCT01297400Skingenix, Inc.Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns | 2026-12-31 |
| NCT07221903University of WashingtonThe Lateral, Anterior, Medial (LAM) Femoral Cutaneous Block: A Case Series Harborview Medical Center, Seattle, WA | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 336 studies in Burns with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objectives and rationale: Optimal burn management involves removing all the dead or burned tissue as early as feasible and cover with an autograft called split thickness skin graft (STSG) taken from the patient. This procedure creates a new wound on the patient and sometimes, when the burn covers very large portion of the patient body, there is a lack of healthy skin to use for this purpose. Under those circumstances, donated cadaver skin is used as a temporary coverage until the patient´s own donor site wound has healed enough to be used again.
The proposed clinical study aims to determine if treatment with fish skin is an alternative to cadaver skin as a temporary coverage for debrided full-thickness burns prior to STSG in terms of autograft take, time to heal, quality of healing (scarring), pain and adverse effects.
Mortality after severe burns has diminished during the last decades and survival is no longer considered the primary end point of care. More attention is paid to the final functional and cosmetic outcome of the affected area but outcomes are still far from optimal. For the time being, one of the main goals in burn treatment is to achieve reduced scar formation from the time of injury. A temporary or permanent covering of the wound bed should be achieved at the time of excision. In burn wounds the gold standard is to use split thickness skin graft, or STSG, which includes epidermis, basement membrane, and a part of upper dermis. Yet the use of skin grafts has many shortcomings: there is only a limited amount of skin available for grafting, the donor sites are susceptible to infections, to pain, to pigmentation changes, and to scarring especially when re harvested. Therefore, for complicated burns, initial treatment is often with temporary coverage where cadaver skin has been the accepted standard of care.
In recent years there has been progress in the development of advanced wound care products. This has resulted in a third generation of wound treatment, known as acellular dermal grafts or skin substitutes.
Aims The goal of this clinical trial is to demonstrate that fish skin is an alternative to cadaver skin as early cover before STSG in burn wounds. This trial will be open to patients who are scheduled to receive meshed STSG of any ratio. Fish skin or cadaver skin will be applied after initial debridement in order to prepare the wound area for STSG.
5 to 10 patients will be prospectively enrolled and two burn sites on their body will randomized to initial treatment after debridement with either fish skin or cadaver skin for 7+/-3 days. After the initial treatment, the test sites will be grafted with STSG.
The histological differences and the functional outcomes will be assessed for 12 months.
Products will be applied by experienced burn surgeons at a burn center. At approximately Day 7, or when the treating physician deems the wound to be ready for grafting, the products will be removed. Prior to grafting, a second blinded burn surgeon will assess the burn wound bed.
Important dates for blinding are on Day 7 prior to STSG treatment and on Days 14, 21 and 28 for graft take, epithelialisation and wound closure. Scar assessment at 3 and 12 months via the Vancouver Scar Sale will also be fully blinded.
Key interventions:
Randomized to either cadaver skin or fish skin after initial debridement Two areas each of 10-20 x 7 cm side by side. Other areas will be treated as per local Standard of care (SOC). Concomitant medications will be given, e.g. painkiller, antibiotics, as needed.
Wound dressings changed approximately every three days until allograft or xenograft removal.
Approximately one week after placement the fish skin and cadaver allografts removed as required.
Subsequent meshed autograft placement if donor sites are available. Autografts covered with secondary antimicrobial/silver dressing and dressings approximately every 3 days until healed.
Autografts monitored for adherence, color, autograft take, and visual signs of infection.
During the operation, a 3 or 4 mm punch biopsy will be harvested from the excised wound bed before covering with any material.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant or legally authorized representative is willing and able to give for participation in the clinical trial.
Exclusion Criteria:
Declined consent
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only fish skin.
Device: Fish skin
All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only cadaver skin.
Device: Cadaver skin
One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
Also known as: Marigen TM, Kerecis Omega3 Burn
One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
Proportions of wounds that have healed
Wounds which have reached at least 95% epithelialization
Time frame: At 3 weeks days after STSG
Percentage of wound area exhibiting graft failure
The proportion of the wound area in which the graft does not take
Time frame: At 2 weeks after STSG
Full epithelialization of wound
Number of wounds fully epithelialized
Time frame: At 2 weeks after STSG
Scarring estimated with the Vancouver Scar Scale (VSS)
Vascularity (0-3), pigmentation (0-3), pliability (0-3), height (0-3), Total score;0=Best, 12=worst
Time frame: At 12 months after STSG
Inflammation profiling of wound punch biopsies as assessed by histology
Histological analysis of punch wound biopsies via standard H\&E staining, or staining for known inflammatory markers (TNF-alpha, IL-1b, IL-6, IL-8)
Time frame: Before STSG, 2 and 3 weeks and 12 months after STSG
Average number of antibiotics treatments per patient
Average number of antibiotics treatments per patient
Time frame: At all treatments appointments until 4 weeks after STSG
Pain assessed by the Visual Analog Scale (VAS) before and after dressing changes
Pain by the Visual Analog Scale (VAS) on a scale of 0-10, 0=no pain, 10= pain as bad as it could be
Time frame: At all treatments appointments until 3 weeks after STSG
Bleeding time
Average time in seconds to achieve hemostasis during dressing changes
Time frame: At all treatments appointments until 3 weeks after STSG
Dermatitis
Incidence of dermatitis
Time frame: At all treatments appointments until 3 weeks after STSG
Ease-of-use
Ease-of-use as judged by attending physician on a VAS scale of 0=extremely difficult to use to 10=Very easy to use
Time frame: Day 0 when grafts are initially applied after debridement
Incidence of hematoma
Nr of wounds which develop a hematoma
Time frame: At all treatments appointments until 3 weeks after STSG
Inflammatory profiling of wound punch biopsies as assessed by mass spectrometry
Mass spectrometry analysis of punch wound biopsies, investigating known inflammatory markers (TNF-alpha, IL-1b, IL-6, IL-8)
Time frame: Before STSG, 2 and 3 weeks and 12 months after STSG
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Feb 2019 to primary completion in Jun 2021, 27 months.
Of 29 industry-sponsored interventional studies with no phase under Burns, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 27. This study's 27 months is above that.
Counting every sponsor, half of 240 studies reached it within 15 months; a quarter within 6 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.